Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. company was founded in 1996 and is based in South San Francisco, California. Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Its product development portfolio includes R788, which is in Phase 2b clinical trial for the treatment of rheumatoid arthritis (RA); a Phase 2 clinical trial for the treatment of immune thrombocytopenia purpura, B-cell lymphoma, and T-cell lymphoma; and a preclinical stage for the treatment of lupus. Rigel company's products also include R348, which is in Phase 1 clinical trial for Psoriasis; R763, which is in Phase 1 clinical trial in the area of oncology; and R343, a Phase 1 clinical trial product for asthma. It has collaboration agreements with Janssen Pharmaceutica N.V.; Pfizer, Inc.; Novartis Pharma AG; Daiichi Pharmaceuticals Co., Ltd.; Merck & Co., Inc.; and Merck Serono.
Contact Details
Office Address
Rigel Pharmaceuticals, Inc.
1180 Veterans Boulevard
South San Francisco, CA, USA 94080
Phone: (650) 624-1100
Fax: (650) 624-1101
Executives
Chairman, Chief Exec. Officer, Pres and Chairman of Fin. Committee
Mr. James M. Gower
Co-Founder, Pres of Discovery & Research
Dr. Donald G. Payan